Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul>
<li>The exploration and development Company with projects in Greenland and Finland has entered into a Binding Head of Terms with USFM Corporation to fund $30m to earn 51% of the DiskoNuussuaq project in West Greenland.</li>
<li>80 Mile as the operator and will receive a management fee of 12.5% of the total expenditure as well as a £0.5m payment upon signing definitive agreements.</li>
<li>The new funds are to be directed towards drilling rather than reprocessing data with a minimum of $10m to be spent within 10 months of the signing. </li>
</ul>


The exploration and development Company with projects in Greenland and Finland has entered into a Binding Head of Terms with USFM Corporation to fund $30m to earn 51% of the DiskoNuussuaq project in West Greenland.
80 Mile as the operator and will receive a management fee of 12.5% of the total expenditure as well as a £0.5m payment upon signing definitive agreements.
The new funds are to be directed towards drilling rather than reprocessing data with a minimum of $10m to be spent within 10 months of the signing. 


Hybridan Small Cap Feast: 03 November 2025

<ul>
<li>Angle 2.20p £8.87m (AGL.L) The precision intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development, and clinical oncology revises its business strategy.</li>
<li>The Chairman, Dr Jan Groen, has moved into an executive role to lead the Company as it focuses on tight cost control, accelerated commercial progress, and a clear plan towards becoming a sustainable business.</li>
<li>As part of its revised strategy, the Company proposes to change its name to Ce1LBxHealth plc to reflects the sharpened focus on the provision of high-value CTC-based precision diagnostic testing. </li>
</ul>


Angle 2.20p £8.87m (AGL.L) The precision intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development, and clinical oncology revises its business strategy.
The Chairman, Dr Jan Groen, has moved into an executive role to lead the Company as it focuses on tight cost control, accelerated commercial progress, and a clear plan towards becoming a sustainable business.
As part of its revised strategy, the Company proposes to change its name to Ce1LBxHealth plc to reflects the sharpened focus on the provision of high-value CTC-based precision diagnostic testing. 


Xeros Technology Group Plc - Hybridan Small Cap Feast: 08/10/2025

Beeks Financial Cloud Group / Equity Bottom-Up

<ul>
<li>The biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases, announces that it has concluded a positive Type C meeting with the US Food and Drug Administration (FDA) for AT278 in people with both type 1 and type 2 diabetes with high daily insulin needs.</li>
<li>The purpose of the meeting was to discuss the design of a proposed Phase 2 clinical study for AT278 delivered by continuous infusion via an Automated Insulin Delivery (AID) system, ahead of a planned Investigational New Drug (IND) submission.</li>
<li>Arecor reports they are on track to commence Phase 2 study in mid-2026, subject to further funding.</li>
</ul>


The biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases, announces that it has concluded a positive Type C meeting with the US Food and Drug Administration (FDA) for AT278 in people with both type 1 and type 2 diabetes with high daily insulin needs.
The purpose of the meeting was to discuss the design of a proposed Phase 2 clinical study for AT278 delivered by continuous infusion via an Automated Insulin Delivery (AID) system, ahead of a planned Investigational New Drug (IND) submission.
Arecor reports they are on track to commence Phase 2 study in mid-2026, subject to further funding.


<ul>
<li>1Spatial 44.5p £56.76m (SPA.L) The global Location Master Data Management software and solutions Company announces finals to January 2025.</li>
<li>There is a 3% increase in revenue to £33.4m of which 62% is recurring up from 56%, last year.</li>
<li>The operating profit decreased to £0.9m from £1.4m reflecting higher costs with a net debt of £1m compared to net cash of £1.1m. </li>
</ul>


1Spatial 44.5p £56.76m (SPA.L) The global Location Master Data Management software and solutions Company announces finals to January 2025.
There is a 3% increase in revenue to £33.4m of which 62% is recurring up from 56%, last year.
The operating profit decreased to £0.9m from £1.4m reflecting higher costs with a net debt of £1m compared to net cash of £1.1m. 


<ul>
<li>The provider of Decision Intelligence software for service operations, provided an update on trading for the year ended 31 March 2025.</li>
<li>Group revenue is expected to have increased by 13% or 15% on a constant currency basis, to approximately £30.4m, reflecting upsell of the latest iterations of its Decision Intelligence software and the successful go live with several major new customers.</li>
<li>SaaS revenues increased by approximately 13%, or 14% on a constant currency basis, up from 8% growth in the prior year. </li>
</ul>


The provider of Decision Intelligence software for service operations, provided an update on trading for the year ended 31 March 2025.
Group revenue is expected to have increased by 13% or 15% on a constant currency basis, to approximately £30.4m, reflecting upsell of the latest iterations of its Decision Intelligence software and the successful go live with several major new customers.
SaaS revenues increased by approximately 13%, or 14% on a constant currency basis, up from 8% growth in the prior year. 


United Kingdom

Fusion Antibodies is a Collaborative Research Organisation (CRO) specializing in antibody discovery, engineering, and supply. The company offers a range of services including antibody generation, development, production, characterization, and optimization for therapeutic drug and diagnostic applications. Fusion Antibodies is headquartered in Belfast, United Kingdom, and was established in 2001.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Fusion Antibodies (FAB LN)

Hybridan Small Cap Feast: 03 November 2025

0 Mile as the operator and will receive a management fee of 12.5% of the total expenditure as well as a £0.5m payment upon signing definitive...

Hybridan

Xeros Technology Group Plc - Hybridan Small Cap Feast: 08/10/2025

The precision intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development, and...

Hybridan

Hybridan Small Cap Feast: 04/09/2025

The purpose of the meeting was to discuss the design of a proposed Phase 2 clinical study for AT278 delivered by continuous infusion via an...

Hybridan

Hybridan Small Cap Feast: 07/05/2025

1Spatial 44.5p £56.76m (SPA.L) The global Location Master Data Management software and solutions Company announces finals to January 2025.

Hybridan

Hybridan Small Cap Feast: 24/04/2025

The provider of Decision Intelligence software for service operations, provided an update on trading for the year ended 31 March 2025.

Hybridan

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)